Vanta Bioscience Ltd.
Snapshot View

139.00 0.00

30 July 2021, 04:00:00 P.M.
Volume: 4,500

Overview View Details

Sector Miscellaneous Compare with Sector peers
Industry Miscellaneous Compare with Industry peers
Website http://www.vantabio.com
Financial Indicators
Market Cap 87.74 Cr.
Earnings per share (EPS) 0.71 Trailing Twelve Months Ending 2021-03
Price-Earning Ratio (PE) 194.97 Trailing Twelve Months Ending 2021-03
Industry PE 113.69 Trailing Twelve Months Ending 2021-03
Book Value / Share 37.18 Trailing Twelve Months Ending 2021-03
Price to Book Value 3.74 Calculated using Price: 139.00
Dividend Yield 0.00 Period Ending 2020-03
No. of Shares Subscribed 0.63 Cr. 6,312,000 Shares
FaceValue 10
Company Profile

Vanta Bioscience (VBS) was originally incorporated as a private limited company under the Companies Act, 2013 pursuant to a certificate of incorporation issued by the Registrar of Companies, Hyderabad dated April 29, 2016 with the name ‘Vanta Bioscience Private Limited’. Their Company was converted into a public limited company pursuant to approval of the shareholders at an extraordinary general meeting held on February 13, 2017 and consequently, the name of the Company was changed to ‘Vanta Bioscience Limited’ and a fresh certificate of incorporation consequent upon conversion to public limited company was issued by the Registrar of Companies, Hyderabad on March 17, 2017.

One of the major services of VBL is conducting variety of in vitro (cell, tissue and organisms) and in vivo (animal) toxicology studies for its diverse clients as per various regulatory requirements from across the world. Toxicology is a branch of biology, chemistry, and pharmacology concerned with the study of the adverse effects of chemicals on living organisms. It also studies the harmful effects of chemical, biological and physical agents in biological systems that establish the extent of damage in living organisms. The relationship between dose and its effects on the exposed organism is of high significance in toxicology. Toxicology and safety assessment are sometimes used interchangeably and considered as synonymous.

Business area of the company

The company is a preclinical contract research organization, offering a host of preclinical safety assessment services for clientele from Pharmaceutical, Medical Devices, Nutraceuticals, Feed Additive, Biotech, Agrochemicals, Cosmetics, and Chemical industries. In addition they also provide risk assessment services for evaluating the safety of the Active Pharmaceutical Ingredients (API), excipients, extractable and leachables including pharmaceutical impurities resulting due to manufacturing process or due to degradation of the product. VBS also provides expert services for determination of health based exposure limits (e.g. permitted daily exposure (PDE) or allowable daily exposure (ADE) including occupational exposure limits (OEL) for pharmaceutical manufacturers. Their services include toxicology, batch release tests, biocompatibility studies, chemical safety, and diet formulation.

Major Events & Milestones:

  • 2016: Incorporation of the Company.
  • 2017:  The Company concluded the purchase of the preclinical CRO facility at Gummidipundi, Chennai from Kemin Industries South Asia Private Limited which was named as - Vanta Bioscience? (a toxicology division of Kemin Industries South Asia Private Limited) along with leasehold rights in 4.8 acres of land situated at Plot K2B, SIPCOT Industrial Estate, Gummidipundi, Chennai - 601 201.

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
1 Week
-2.04%
1 Month
-7.95%
3 Month
-14.83%
6 Month
+2.96%
1 Year
-0.64%
2 Year
+10.32%
5 Year
2 years 2019-03 2020-03
Return on Equity (%) 3.14 4.43
Return on Capital Employed (%) 7.87 8.62
Return on Assets (%) 1.78 2.31

Balance Sheet View Details

Particulars 2 years 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Shh. Funds 22 23
Non Curr. Liab. 13 14
Curr. Liab. 3 10
Minority Int. 1 1
Equity & Liab. 39 49
Non Curr. Assets 22 29
Curr. Assets 17 20
Misc. Exp. not W/O
Total Assets 39 49

Profit Loss View Details

Particulars 2 years 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Net Sales 12 14
Other Income 0 0
Total Income 12 14
Total Expenditure -9 -9
PBIDT 4 4
Interest -2 -2
Depreciation -1 -1
Taxation 0 0
Exceptional Items
PAT 1 1

Cash Flow View Details

Particulars 2 years 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Cash Fr. Operatn. -1 2
Cash Fr. Inv. -6 -7
Cash Fr. Finan. 10 2
Net Change 3 -3
Cash & Cash Eqvt 3 0

Shareholding Pattern View Details

9 Qtrs 2017-03 (%) 2017-09 (%) 2018-03 (%) 2018-09 (%) 2019-03 (%) 2019-09 (%) 2020-03 (%) 2020-09 (%) 2021-03 (%)
Promoter 98.43 72.45 72.45 72.45 69.93 69.93 69.93 69.93 69.11
Public 1.57 27.55 27.55 27.55 30.07 30.07 30.07 30.07 30.89
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Thu, 29 Jul 2021
Intimation Regarding GLP Re-Certification In Vanta Bioscience Limited And Commencement Of Commercial Operations In Vayam Research Solutions Limited
Intimation regarding GLP re-certification in Vanta Bioscience Limited and commencement of commercial operations in Vayam Research Solutions Limited
Tue, 13 Jul 2021
Intimation Regarding NABL'S Recommendation To Continue The Biological Testing Accreditation Granted To The Company
We are glad to inform you that NABL has completed its surveillance audit and has recommended continuation of Companys existing accreditation in accordance with ISO/IEC 17025:2017 in the discipline of Biological Testing without any observations or remarks.
Mon, 05 Jul 2021
Statement Of Investor Complaints For The Quarter Ended June 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter
0000
Name of the Signatory :- Zoheb Sayani
Designation :- Company Secretary and Compliance Officer

Technical Scans View Details

Fri, 30 Jul 2021
Stock Underperforming Benchmark Index in both 1 Week and 3 Month Stock Underperforming Benchmark Index in both 1 Week and 3 Month
Strongly Underperforming Benchmark index Strongly Underperforming Benchmark index
Both SRS And ARS Below Zero Both SRS And ARS Below Zero
Wed, 28 Jul 2021
Stock Underperforming Benchmark Index in both 1 Week and 3 Month Stock Underperforming Benchmark Index in both 1 Week and 3 Month
Strongly Underperforming Benchmark index Strongly Underperforming Benchmark index

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Syngene International Ltd. 25,560.80 637.75 +2.0%
Quess Corp Ltd. 12,813.25 867.20 +6.1%
RattanIndia Enterprises Ltd. 9,247.38 66.90 +4.9%
TeamLease Services Ltd. 7,276.47 4,256.05 +8.3%
SIS Ltd. 7,118.18 485.00 +0.7%
Sun Pharma Advanced Research Company Ltd. 7,083.14 270.30 +10.1%
Just Dial Ltd. 6,013.21 964.15 -0.2%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Syngene International Ltd. Consolidated 2021-06 60.26 637.75 +2.0%
Quess Corp Ltd. Consolidated 2021-03 221.39 867.20 +6.1%
RattanIndia Enterprises Ltd. Consolidated 2021-03 0.00 66.90 +4.9%
TeamLease Services Ltd. Consolidated 2021-06 83.19 4,256.05 +8.3%
SIS Ltd. Consolidated 2021-06 19.27 485.00 +0.7%
Sun Pharma Advanced Research Company Ltd. Standalone 2021-06 0.00 270.30 +10.1%
Just Dial Ltd. Consolidated 2021-06 47.23 964.15 -0.2%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Syngene International Ltd. Consolidated 2021-06 9.06 637.75 +2.0%
Quess Corp Ltd. Consolidated 2021-03 5.47 867.20 +6.1%
RattanIndia Enterprises Ltd. Consolidated 2021-03 108.99 66.90 +4.9%
TeamLease Services Ltd. Consolidated 2021-06 10.73 4,256.05 +8.3%
SIS Ltd. Consolidated 2021-06 3.99 485.00 +0.7%
Sun Pharma Advanced Research Company Ltd. Standalone 2021-06 -30.64 270.30 +10.1%
Just Dial Ltd. Consolidated 2021-06 4.77 964.15 -0.2%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Syngene International Ltd. Consolidated 2021-03 0.28 637.75 +2.0%
Quess Corp Ltd. Consolidated 2020-03 0.51 867.20 +6.1%
RattanIndia Enterprises Ltd. Consolidated 2020-03 0.00 66.90 +4.9%
TeamLease Services Ltd. Consolidated 2020-03 0.14 4,256.05 +8.3%
SIS Ltd. Consolidated 2021-03 0.74 485.00 +0.7%
Sun Pharma Advanced Research Company Ltd. Standalone 2020-03 -3.67 270.30 +10.1%
Just Dial Ltd. Consolidated 2020-03 0.00 964.15 -0.2%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Syngene International Ltd. Consolidated 2021-03 16.59 637.75 +2.0%
Quess Corp Ltd. Consolidated 2020-03 -16.80 867.20 +6.1%
RattanIndia Enterprises Ltd. Consolidated 2020-03 -0.24 66.90 +4.9%
TeamLease Services Ltd. Consolidated 2020-03 6.75 4,256.05 +8.3%
SIS Ltd. Consolidated 2021-03 23.02 485.00 +0.7%
Sun Pharma Advanced Research Company Ltd. Standalone 2020-03 -225.08 270.30 +10.1%
Just Dial Ltd. Consolidated 2020-03 24.85 964.15 -0.2%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Syngene International Ltd. Consolidated 2021-03 15.40 637.75 +2.0%
Quess Corp Ltd. Consolidated 2020-03 -5.79 867.20 +6.1%
RattanIndia Enterprises Ltd. Consolidated 2020-03 0.63 66.90 +4.9%
TeamLease Services Ltd. Consolidated 2020-03 16.25 4,256.05 +8.3%
SIS Ltd. Consolidated 2021-03 21.05 485.00 +0.7%
Sun Pharma Advanced Research Company Ltd. Standalone 2020-03 -178.22 270.30 +10.1%
Just Dial Ltd. Consolidated 2020-03 31.48 964.15 -0.2%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Syngene International Ltd. Consolidated 2021-03 2,184.30 637.75 +2.0%
Quess Corp Ltd. Consolidated 2020-03 10,991.48 867.20 +6.1%
RattanIndia Enterprises Ltd. Consolidated 2020-03 66.90 +4.9%
TeamLease Services Ltd. Consolidated 2020-03 5,200.72 4,256.05 +8.3%
SIS Ltd. Consolidated 2021-03 9,127.30 485.00 +0.7%
Sun Pharma Advanced Research Company Ltd. Standalone 2020-03 76.81 270.30 +10.1%
Just Dial Ltd. Consolidated 2020-03 953.11 964.15 -0.2%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Syngene International Ltd. Consolidated 2021-03 404.90 637.75 +2.0%
Quess Corp Ltd. Consolidated 2020-03 -418.05 867.20 +6.1%
RattanIndia Enterprises Ltd. Consolidated 2020-03 -0.38 66.90 +4.9%
TeamLease Services Ltd. Consolidated 2020-03 37.06 4,256.05 +8.3%
SIS Ltd. Consolidated 2021-03 366.66 485.00 +0.7%
Sun Pharma Advanced Research Company Ltd. Standalone 2020-03 -312.40 270.30 +10.1%
Just Dial Ltd. Consolidated 2020-03 272.31 964.15 -0.2%